Skip to main content
HROW logo

HROW

Harrow, Inc.
$46.15 +1.22 (+2.72%) At close · Jul 7
Market Cap
$1.68B
Shares
37,275,107

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$272.3M +36.4%
FY2025 Revenue FY2013–FY2025
Net Income
-$5.14M +70.6%
FY2025 Net Income FY2006–FY2025
Gross Margin
75.05% -0.3pp
FY2025 Gross Margin FY2013–FY2025
Operating Margin
11.21% +6.8pp
FY2025 Operating Margin FY2013–FY2025
Diluted EPS
-$0.14 +71.4%
FY2025 Diluted EPS FY2017–FY2025
Operating Cash Flow
$43.86M +297.6%
FY2025 Operating Cash Flow FY2010–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2027 (G) FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010 FY2009 FY2008 FY2007 FY2006 FY2005 FY2004 FY2003 FY2002 FY2001
$250M $350M – $365M $268.68M $272.3M $199.61M $130.19M $88.6M $72.48M $48.87M $51.17M $41.37M $26.77M $19.94M $9.72M $1.66M $10K
-$5.44M -$2.24M -$2.5M -$2.73M -$3.03M -$2.77M -$1.11M $29K
$69.57M $67.93M $49.25M $39.64M $25.38M $18.21M $14.46M $16.75M $16.52M $13.51M
$199.11M $204.37M $150.37M $90.55M $63.21M $54.26M $34.41M $34.42M $24.85M $13.27M $10.11M $4.51M $567K $10K
75.05% 75.33% 69.55% 71.35% 74.87% 70.41% 67.26% 60.07% 49.56% 50.7% 46.42% 34.16% 100%
$23.81M $20.94M $12.23M $6.65M $3.05M $11.08M $2.41M $2.08M $825K $413K $739K $332K $237K $1.62M $1.3M $111.55K $194.59K
$7.06M $7.38M $6.5M $2.39M $85.89K
$17.96M $17.57M $12.5M $8.09M $5.99M
$155.63M $152.91M $129.06M $83.09M $58.24M $41.32M $31.25M $33.09M $29.24M $25.02M $18.63M $2.98M $827.67K $2.31M
$17.89M $16.99M $11.78M $10.08M $1.58M $161K $167K $209K $235K $364K $351K $355K $48K
$1.31M $1.32M $1.27M $1.06M $1.25M $1.58M $1.7M $1.94M $1.61M $1.4M $1.06M $255K $37K
$179.44M $173.85M $141.55M $90.12M $61.29M $52.65M $34.02M $39.21M $30.07M $25.43M
$120K
$19.67M $30.52M $8.82M $431K $1.92M $1.61M $385K -$4.8M -$5.22M -$12.16M -$15.88M -$14.82M -$10.15M -$7.69M -$4.18M -$939.23K -$2.5M
11.21% 4.42% 0.33% 2.17% 2.23% 0.79% -9.37% -12.61% -45.43% -79.64% -152.55% -611.27% -76868.79%
$20.97M $31.83M $10.09M $1.49M $3.17M $3.19M $2.09M -$2.86M -$3.61M -$10.76M -$14.83M -$14.57M -$10.11M
$23.13M $24.18M $22.79M $21.32M $7.24M $5.44M $3800 $1.73M $75K $55.48K
$32.45K $43.76K $142.99K $0 $512
-$31.88M -$26.14M -$24.14M -$15.93M -$19.49M -$3.8M $4.68M $19.84M -$757K -$3.32M -$1.08M $29K $43.76K
-$3.17M $3.09M -$2.91M -$10.13M
-$11.17M -$1.37M -$17.32M -$23.71M -$14.01M -$17.87M -$3.42M -$117K $14.63M -$12.92M -$19.2M
$3.77M $161K $701K $75K $133K $4000 $8000 -$935K -$111K $5000 $3000 $1600 $0
-$14.96M -$5.14M -$17.48M -$24.41M -$14.09M -$18.01M -$3.36M $168K $14.63M -$11.99M -$19.09M -$15.9M -$10.12M -$7.64M -$5.38M -$953.94K -$2.53M -$4.55M -$3.3M -$4.28M -$584.23K -$539.62K -$508.23K -$207.2K -$228.22K -$208.42K
-1.89% -8.76% -18.75% -15.9% -24.85% -6.87% 0.33% 35.35% -44.76% -95.71% -163.64% -609.52% -76431.24%
-$62K -$293K
-$4.99M -$17.48M -$24.41M -$14.09M -$18.48M -$3.36M -$10.12M -$7.64M -$5.58M -$1.05M -$2.53M
USD/shares -$0.14 -$0.49 -$0.75 -$0.51 -$0.69 -$0.13 $0.01 $0.67 -$0.60
USD/shares -$0.14 -$0.49 -$0.75 -$0.51 -$0.13 $0.01 $0.61 -$0.60
shares 36.76M 35.65M 32.62M 27.46M 26.76M 25.9M 25.32M 21.92M 20.03M 12.74M 9.58M 9.13M 8.66M 4.49M 397.8K
shares 36.76M 35.65M 32.62M 27.46M 26.76M 25.9M 26.47M 23.81M 20.03M 12.74M 9.58M 9.13M 8.66M 4.49M 397.8K
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals. Showing the latest 26 of 27 periods — chart a line item for full history.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2013–FY2014: $13.19K in buybacks.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component 2025-12-31 2024-12-31 2023-12-31 2021-12-31 2020-12-31 2019-12-31
Branded $195,756,000 $116,115,000 $50,258,000
Imprimis Rx $76,547,000 $83,499,000 $79,935,000
Pharmaceutical Compounding $72,476,000 $48,871,000 $51,165,000

By Product & Service (USD)

Component 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Product Sales Net $271,909,000 $198,619,000 $117,447,000 $83,524,000 $69,104,000 $48,479,000 $51,137,000
VEVYE $88,688,000 $28,061,000 $1,766,000
IHEEZO $81,348,000 $49,303,000 $20,621,000
Other Products $25,326,000 $37,836,000 $15,125,000
Other Revenue $394,000 $915,000 $12,746,000
Other Revenues $394,000 $995,000 $12,746,000 $5,071,000 $3,372,000 $392,000 $28,000
Commissions $3,866,000 $3,253,000 $356,000
Transfer of Acquired Product Sales Profits $995,000 $12,746,000 $1,205,000
Transfer Of Profit $1,205,000 $99,000
License $20,000 $36,000 $28,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component 2025-12-31 2024-12-31 2023-12-31
Branded $53,535,000 $29,257,000 $18,829,000
Imprimis Rx $15,124,000 $31,928,000 $22,781,000

Operating Margin by Segment (%)

Component 2025-12-31 2024-12-31 2023-12-31
Branded 27.3% 25.2% 37.5%
Imprimis Rx 19.8% 38.2% 28.5%
Key facts CIK 1360214 CUSIP 415858109 13F (30d) 8 filings 8 filers Visit website Investor relations